

Product datasheet for TL303045V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

NALP4 (NLRP4) Human shRNA Lentiviral Particle (Locus ID 147945)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: NALP4 (NLRP4) Human shRNA Lentiviral Particle (Locus ID 147945)

Locus ID: 147945

Synonyms: CLR19.5; CT58; NALP4; PAN2; PYPAF4; RNH2

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: NLRP4 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 134444, NM 134444.1, NM 134444.2, NM 134444.3, NM 134444.4, BC050326,

BC050326.1, BC012789, BC016443, BC021272, NM 134444.5

UniProt ID: Q96MN2

Summary: The protein encoded by this gene is a member of the nucleotide-binding and leucine-rich

repeat receptor (NLR) family, and is predicted to contain an N-terminal pyrin effector domain (PYD), a centrally-located nucleotide-binding and oligomerization domain (NACHT) and C-terminal leucine-rich repeats (LRR). This gene product has a demonstrated role as a negative regulator of autophagy and type I interferon signaling pathways as a result of protein

interactions with its NACHT domain. The PYD domain has also been shown to be important in

the inhibition of NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells).

[provided by RefSeq, Dec 2016]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).